Syndax Pharmaceuticals (SNDX) Cash from Investing Activities (2015 - 2026)

Syndax Pharmaceuticals' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 59.22% year-over-year to $38.4 million; the TTM figure through Mar 2026 stood at $234.3 million (up 993.05% YoY), while the FY2025 annual figure was $290.0 million, up 231.97% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $38.4 million, down from $81.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $94.1 million in Q1 2025, with the low at -$269.0 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is $38.4 million (2026), against an average of $2.4 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 689.97% in 2023, then plunged 1551.15% in 2024.
• Syndax Pharmaceuticals' Cash from Investing Activities stood at -$137.6 million in 2022, then surged by 88.16% to -$16.3 million in 2023, then slumped by 1551.15% to -$269.0 million in 2024, then soared by 130.33% to $81.6 million in 2025, then tumbled by 52.94% to $38.4 million in 2026.
• Business Quant data shows SNDX's Cash from Investing Activities at $38.4 million in Q1 2026, $81.6 million in Q4 2025, and $72.4 million in Q3 2025.